Aurobindo Pharma Limited. Investor Presentation
|
|
- Miles Nash
- 5 years ago
- Views:
Transcription
1 Aurobindo Pharma Limited Investor Presentation May 2015
2 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance. Aurobindo Pharma undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances. For updates and specific queries, please visit our website www. aurobindo.com
3 Aurobindo s Journey 2006: Acquired Milpharm (UK) 2007: Acquired formulations facility in USA and Pharmacin Netherlands) * Massive Investment in building manufacturing marketing & IPR capabilities * Leadership in global ARV generic 2014: Acquired commercial operations in 7 Western European countries from Actavis and Natrol Inc. an established nutraceuticals company in USA Differentiated offerings in Oral & Injectable products; new technology & market access 1992: Began exporting to RoW markets (API) 2001: Setup first overseas plant (China) Diversified API portfolio in SSP and Cephalosporin with leadership in anti-infectives 2012: First approval of Controlled Substance formulations in USA Set up AuroPeptide to foray into Peptide business 1995: Listings in the Indian Stock Exchanges 2002: Began production of Formulations 2010: Commenced operations of SEZ Unit VII and Aurolife, USA facilities and divested Chinese Penicillin-G facility 2013: Commenced marketing specialty injectables products in USA though AuroMedics Focus on Penem, Onco & Hormones 2
4 Company Overview Net Operating Income (INR Bn) Among the top pharmaceutical companies from India One of the leading vertically integrated pharma companies from India in terms of ex-india sales A global company with more than 85% of operating income coming from international operations Leading the Gx footprint in Europe, having a strong presence among India based Gx-companies Sales by Segment (%) Evolving focus on complex molecules, differentiated technology platforms and specialty products Wide diverse product basket with 2,100+ formulation filings & c.2,500 API filings worldwide A well integrated, Export Driven Gx-Pharma MNC with large scale of operations and wide product offerings 3
5 Formulation Business Drivers Portfolio mix is changing towards niche and high-value products Earlier Pipeline First 150 ANDA filings Current Pipeline 376 ANDA filings as at 31-Mar-2015 Future Pipeline Will also include Oncolytics, Peptides, Steroids, Branded Gx, Dry Powder Inhalers, Patches & Films Wide diverse product and technology offerings In-house R&D, Regulatory, QA & QC Backward integration/ improved product mix/ cross-selling Advance market focus. Uncompromised quality Strong leadership and market intelligence Speed to market and operational efficiencies 4
6 US Generics Aurobindo Oral Rx AuroLife Manufacturing / R&D AuroMedics Injectables AuroHealth Pharma OTC Natrol Nutraceuticals Aurobindo USA Cumulative ANDA Filings and Approvals Revenues ` Bn 5
7 EU Generics : Focus Markets Focus Markets Products Filed and in Market FY14 Revenues FY15 Revenue Market Insights France ` 10.3Bn Low Gx penetration at 30-35%. Market increasingly shifting towards Gx but characterized by brand-loyalty amidst pricing pressure. Germany 287 ` 0.5Bn ` 7.3Bn Among the largest European pharma market, which has gradually transformed from a ethically distributed branded Gx market to a tender-driven one. Netherlands 331 ` 0.9Bn ` 3.9Bn With the publication of the supply prices, accessibility of information has improved to promote Gx, with the knock-down effect on the prices and margins. Spain 204 ` 1.1Bn ` 2.9Bn Low Gx penetration. Gx market is growing rapidly on back of healthcare reforms Portugal 260 ` 0.3Bn ` 1.4Bn promoting usage of Gx. UK 93 ` 1.8Bn ` 2.1Bn Highly competitive market with high Gx penetration and low entry barriers. Characterized by high degree of fragmentation and indirect price control by the Govt Italy ` 1.4Bn Gx market is relatively small due to extended patent protection and limited measures by the Govt to improve generic usage. Revenues ` Bn Acquisition of Actavis Western European Commercial Operations Strategic and transformative : leading Indian pharma company in Europe Increased scale of operations Pipeline of 200+ products Hx and Branded Gx platforms to launch own injectable and specialty portfolio Strong and established channel partners New market access France, Italy and Belgium New therapeutic offerings Hormone, Oncolytic, Ophthalmic, Penem Acquired business contributed to ~ ` 25.6 Bn during FY15 6
8 Anti-Retrovirals TGx Treatment with ARV medicines against the retrovirus (HIV), which resides and multiplies within the human body Durable suppression of viral replication to prevent development of HIV, drug resistance and treatment failure Restoration/ preservation of immunologic function Reduction of HIV-related morbidity and mortality Improvement of the patient s quality of life Prevention of onward transmission of HIV infection Globally 35Mn people are HIV+ with 12Mn receiving treatment APL catering to 3Mn HIV+ patients today Large product basket of generic ARV incl. combination drugs and NDAs Formulation facilities approved by USFDA / WHO WHO recently included Tenofovir Triples as First Line Treatment (FLT) Out of $1Bn Tenofovir Triples market, APL s share is only 4% today Revenues ` Bn Abacavir Efavirenz Atazanavir Didanosine Nevirapine Lopinavir Emtricitabine Etravirine Ritonavir Lamivudine Rilpivirine Stavudine Zidovudine Tenofovir 7
9 RoW Generics Focus Markets Brazil South Africa Products Filed and in Market 89 filed 35 approved 336 filed 144 approved FY14 Revenues FY15 Revenue Market Insights ` 1.4Bn ` 1.6Bn 6 th largest pharma market in the world ($25Bn). Largely branded Gx in nature with Gx substitution rising. ~80% spending on medicines is out-of-pocket in nature. Govt s pro-gx reforms is supporting in sharp rise in Gx penetration ` 2.4Bn ` 2.0Bn World s largest HIV population lead to increasing govt directed efforts for ARV therapies. New international pricing system for innovators and benchmarking for Gx players being introduced. New pharmacy dispensing fee further encourage Gx uptake. APL focusing on enhancing presence on private oral and injectable Canada 80 filed ` 0.4Bn ` 0.4Bn Health care system is government funded. Comprehensive coverage includes all physician and hospital costs but not cost of Rx outside hospital. Provinces 60 approved have established drug plans primarily for seniors (age > 65) and the poor Revenues ` Bn Other focus markets being developed Mexico, Columbia Ukraine, Russia Kenya, Tanzania, Ethiopia, Nigeria Vietnam, Malaysia, Philippines Largely driven by ethical promotion of Brands. Rising healthcare costs, capacity constraints and growing economic disparities pose new challenges and provide opportunities to promote Gx. 8
10 The Base Business : API Quality & Reliability of supplies APL offers cost competitiveness and high Captive feed for value-added APL-Gx process chemistry skills coupled with Emerging Market leadership - largest supplier in India commitment to quality. Advance Market (EU, Japan, USA) focus Share of emerging markets in India's overall API Cost efficiencies as well as economies of scale exports has reached 45% from 32% in Serve as preferred source for generics and branded drugs Focus on high value, specialty, small/mid-size products with a limited competition Revenues ` Bn Strong Regulatory Capabilities US DMF 188 EDMF 1601 CoS 114 RoW 681 9
11 Consolidated Financial Performance : Y-o-Y Value ` Mn Q4 FY14-15 Q4 FY13-14 Q3 FY14-15 Q3 FY13-14 Q2 FY14-15 Q2 FY13-14 Q1 FY14-15 Q1 FY13-14 FY14-15 FY13-14 Formulations API Formulations % of sales 78% 68% 79.0% 65.9% 76.6% 63.1% 77.2% 63.0% 78% 65% Net Sales Dossier Income Net Operating Income Gross Margin % 61.5% 53.0% 58.1% 56.1% 52.0% 52.6% 48.0% 54.6% 55.5% Overheads EBIDTA (excl. Fx & other income) % 31.9% 19.3% 30.2% 22.1% 22.9% 22.6% 17.9% 21.2% 26.4% Fx (Gain) / Loss (12) (356) 202 (21) (14) Other Income Finance Cost Depreciation PBT PAT (Loss) (before minority interest) Fx Rate $ 1= `
12 Debt profile Fx Loans in $ Mn Outstanding As on 31-Mar Mar Mar $ = ` ` Mn Fx Loan restated in ` * 43173** Rupee Loan Sales Tax Deferment Gross Debt Cash Balance Net Debt EBIDTA (excl. Fx and Other Income) Net Debt/EBIDTA (x) Finance Cost Cost of debt (%) 3.8% 2.9% 1.9% *Includes $ 67Mn advance paid under escrow bank account towards acquisition of Actavis Western European commercial operations **Includes $104Mn borrowing of account of Natrol Inc, USA 11
13 Thank You For updates and specific queries, please visit our website www. aurobindo.com Corporate Office: WaterMark Building, Level-1 Plot No.11, Survey No. 9 Kondapur, Hitech City, Hyderabad Phone: / ir@aurobindo.com Registered Office: Plot No. 2, Maitrivihar Ameerpet, Hyderabad
14 Annexure Formulation gross sales break-up ` Bn FY FY Q1 Q2 Q3 Q4 FY14 Q1 Q2 Q3 Q4 FY15 USA Europe RoW ARV Total Gross Sales % of Sales 63% 63% 66% 68% 65% 77% 77% 79% 79% 78% X
15 Annexure API gross sales break-up ` Bn FY FY Q1 Q2 Q3 Q4 FY14 Q1 Q2 Q3 Q4 FY15 Cephalosporin SSPs Non-Betalactam Total Gross Sales % of Sales 37% 37% 34% 32% 35% 23% 23% 21% 21% 22% X
16 Annexure Filing details (As on 31 st March 2015) As at Mar 12 As at Mar 13 As at Mar 14 Apr 14-Mar 15 As at Mar 15 Approvals Formulations Advanced markets US FDA ^ (FA: 166 TA: 27) Europe * Dossiers (124 products) SA Registrations (77 products) Canada Dossiers ^ Includes filings made from AuroLife Pharma LLC, USA (net of ANDAs withdrawn) * Includes Multiple Registration of dossiers developed in-house. In addition 3348 Marketing Authorizations acquired from Actavis + Includes duplicate & triplicate dossiers. (net of Registration withdrawn) APIs US FDA EDMF CoS RoW Patents Patents granted 15
17 Annexure Manufacturing base Finished Dose Formulations / Integrated facilities AuroLife USA Non betalactam, Controlled substances Solid Orals Unit III India Non betalactam Solid & Liquid Orals Unit IV India Non betalactam Injectables & Ophthalmic Unit VII (SEZ) India Non betalactam Solid Orals AuroNext India Penem Injectables; Sterile API (EM) Unit VIB India Cephalosporin Solid & Liquid Orals; Injectables (EM) Brazil Brazi SSP / Amoxi Solid & Liquid Orals Unit XII India SSP Solid & Liquid Orals Injectables Eugia India Oncology and Hormones Injectables and Soft Gel Capsules Natrol Inc USA Nutraceuticals Solid & Liquid Orals AuroHealth USA Pharma OTC Liquid Orals Active Ingredients and Intermediates Unit I India Non betalactam Non-sterile API Unit VIII India Non betalactam Non-sterile API Unit XIB India Non betalactam Non-sterile API Unit XIV India Non betalactam Non-sterile API Silicon LS India Penem Non-sterile API Unit IA India Cephalosporin Non-sterile API Unit VIA India Cephalosporin Sterile API Unit V India SSP Sterile & Non-sterile API Unit IX India SSP Non-sterile API Unit II India Betalactum Non-sterile Intermediates Unit XIU India Betalactum Non-sterile API (EM) Approved by Regulatory Agencies as USFDA, UKMHRA, JapanPMDA, WHO, Health-Canada, MCC-SA, TGA, ANVISA Brazil. 16
18 Annexure 5 year financial snapshot Value ` Bn FY2011 FY2012 FY2013 FY2014 FY2015 Net sales Dossier Income Net Operating Income Gross margin % of operating income 50.4% 45.5% 48.9% 55.5% 54.6% EBITDA (before Fx and other income) % to Operating income 22.0% 13.2% 15.2% 26.4% 21.2% Depreciation / Amortization Finance Cost PBT PAT before exceptional items and minority interest Total Shareholder Funds Borrowed funds FCCB Other loans Total Borrowed Funds Borrowed Funds net of Cash Fixed Assets (Gross incl. CWIP) Debt (incl. FCCB) / Shareholders funds (x) Borrowed Funds net of Cash / EBIDTA (x) Asset Turnover Ratio (x)
19 Annexure Key financial indicators in USD $ Mn Q4 FY14-15 Q4 FY14-15 Q3 FY14-15 FY14-15 FY13-14 Average $ = ` US Gx EU Gx RoW Gx ARV Formulations Formulations Betalactam (SSP+Ceph) Non Betalactam API Gross Sales Net Operating Income EBIDTA (excl. Fx & other income) % % % % % Finance Cost Debt As on 31-Mar Mar Mar-15 Closing 1 $ = ` Term Loans * 321** WC (Lines of Credit) Sales Tax Deferment Gross Debt Cash Net Debt *Includes $ 67Mn advance paid under escrow bank account towards acquisition of Actavis Western European commercial operations **Includes $104Mn borrowing of account of Natrol Inc, USA Depreciation Other Income PBT (excl Fx)
20 Annexure Shareholding pattern % As on As on As on As on As on As on As on As on As on Promoter Group 54.9% 54.9% 54.9% 54.7% 54.6% 54.3% 54.1% 54.1% 54.0% FII 16.8% 17.9% 19.8% 21.2% 23.7% 27.5% 27.7% 29.7% 29.6% MF / UTI 10.9% 11.0% 10.9% 10.2% 9.7% 7.7% 7.8% 6.4% 6.2% Insurance 2.5% 1.7% 0.2% 0.1% 0.1% FIs / Banks / Bodies Corporate 5.5% 4.7% 4.2% 3.1% 2.2% 1.7% 1.6% 1.8% 1.6% Non-Institutional Investors 9.4% 9.8% 10.0% 10.7% 9.7% 8.8% 8.8% 8.0% 8.6% 100% 100% 100% 100% 100% 100% 100% 100% 100% Equity base (shares # Mn) Face Value (`) Equity Capital (` Mn) M-Cap at close (` Bn) Shareholder family (# 000)
Investor Presentation
Aurobindo Pharma Limited Investor Presentation Investor Presentation August 2015 May 2015 Forward looking statement This presentation contains statements that constitute forward looking statements including
More informationAurobindo Pharma Limited. Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors November 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationAurobindo Pharma Limited Presentation to Investors
Aurobindo Pharma Limited Presentation to Investors February 2013 Forward looking statement This presentation contains statements that constitute forward looking statements including and without limitation,
More informationINVESTOR PRESENTATION. November 2015
INVESTOR PRESENTATION November 2015 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the implementation
More informationQ4 FY16-17 EARNINGS PRESENTATION. 29 th May 2017
Q4 FY16-17 EARNINGS PRESENTATION 29 th May 2017 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationQ2 FY18-19 EARNINGS PRESENTATION
Q2 FY18-19 EARNINGS PRESENTATION 12 th November 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationQ4 FY17-18 EARNINGS PRESENTATION
Q4 FY17-18 EARNINGS PRESENTATION 28 th May 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to the
More informationQ3 FY17-18 EARNINGS PRESENTATION. 7 th February 2018
Q3 FY17-18 EARNINGS PRESENTATION 7 th February 2018 Disclaimer This presentation contains statements that constitute forward looking statements including and without limitation, statements relating to
More informationAurobindo Pharma Ltd Q1 FY18-19 Financial Results Q1 Q1
NEWS RELEASE 9 th August 2018, Hyderabad, India Consolidated financial results Q1FY18-19 Aurobindo Pharma Ltd Q1 FY18-19 Financial Results Amount in INR Cr Q1 Q1 Q4 FY18-19 FY17-18 FY17-18 Revenue from
More informationNATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza,
(? AUROBINDO Date: November 12, 2018 To To NATIONAL STOCK EXCHANGE OF INDIA BSE LIMITED LIMITED Phiroz Jeejeebhoy Towers, Exchange Plaza, 25 th floor, Dalal Street, Sandra Kurla Complex, Sandra (E), MUMBAI
More informationQ3 FY15-16 Unaudited Financials
NEWS RELEASE 9 th February 2016, Hyderabad, India Q3 Unaudited Financials Amount in INR Cr Q3 Q3 % Chg Q2 % Chg 9 Months FY14-15 (YoY) (QoQ) Consolidated Net Operating Income* 3,495.5 3,166.2 10.4 3,333.5
More informationQ4 FY15-16 and FY15-16 Financial Results. % Chg (YoY) Q3 FY FY15-16 FY14-15 % Chg Consolidated Net Operating Income*
NEWS RELEASE 30 th May 2016, Hyderabad, India Amount in INR Cr Q4 FY15-16 Q4 FY15-16 and FY15-16 Financial Results Q4 FY14-15 % Chg (YoY) Q3 FY15-16 % Chg (QoQ) FY15-16 FY14-15 % Chg Consolidated Net Operating
More informationIndian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route
Aurum Equity Partners LLP Aurum Insights Pharmaceuticals October 2014 Indian Pharma companies are aggressively building out a global franchise through increased M&A and the collaboration route Read more
More informationBUY. Aurobindo Pharma Ltd. Pharmaceuticals RETAIL EQUITY RESEARCH. Well placed to monetise the product pipeline
COMPANY INITIATING REPORT Jun-15 Jul-15 Aug-15 Sep-15 GEOJIT BNP PARIBAS Research Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 RETAIL EQUITY RESEARCH Aurobindo Pharma Ltd. Pharmaceuticals
More informationAurobindo Pharma Ltd Q3 FY17-18 Financial Results Q3 Q3
NEWS RELEASE 7 th February 2018, Hyderabad, India Consolidated financial results Q3FY17-18 Aurobindo Pharma Ltd Q3 FY17-18 Financial Results Amount in INR Cr Q3 Q3 9M 9M FY17-18 FY16-17 FY17-18 FY16-17
More informationLupin Investor Presentation Q3FY14
Lupin Investor Presentation Q3FY14 Vision: To be an innovation led transnational company Safe harbor statement Materials and information provided during this presentation may contain forward looking statements.
More informationWarm Welcome Shareholders. 22nd Annual General Meeting June 10, 2013
Warm Welcome Shareholders 22nd Annual General Meeting June 10, 2013 Performance Snapshot - FY 2012 Revenue * EBITDA * 31% 36% 2291 INR Crores (Except EPS) 562 1748 413 904 920 1188 104 159 320 2008 2009
More informationInvestor Presentation February 2019
Investor Presentation February 2019 Dr. Reddy s Laboratories Limited Hyderabad, India BSE: 500124 NSE: DRREDDY NYSE: RDY Safe Harbor Statement This presentation contains forward-looking statements and
More informationAurobindo Pharma. Institutional Equities. Initiating Coverage. US Business To Drive Growth BUY
Initiating Coverage Institutional Equities Aurobindo Pharma 7 April 16 Reuters: ARBN.BO; Bloomberg: ARBP IN US Business To Drive Growth Aurobindo Pharma (APL) has gradually transformed itself from an API
More informationFormulations Performance Highlights Q3 FY18
Press Release Strides announces Q3 FY18 results Continuing adjusted EBITDA at INR 1,441 Mn Revenues* at INR 7,536 Mn Adjusted PAT* at INR 630 Mn (* for continuing business) Bengaluru, February 9, 2018:
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation May-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Annual Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More information37 th Annual JP Morgan Healthcare Conference. January 8, 2019
37 th Annual JP Morgan Healthcare Conference January 8, 2019 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationLupin Limited Corporate Presentation. May 2009
Lupin Limited Corporate Presentation May 2009 Corporate Highlights Eleventh successive quarter of growth in sales and profits. Growth has been secular across SBUs and regions Particularly strong in US,EU,
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16. Apr Mar. 15 Net Sales : Jan. 15 Mar. 15
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY16 Financials (` In Lacs) Unaudited Audited Particulars Quarter Ended Year Ended Apr. 15 Jun. 15 Jan. 15 Mar. 15 Apr. 14
More informationLUPIN LIMITED. Q3 FY18 Investor Presentation. February 06, 2018
LUPIN LIMITED Q3 FY18 Investor Presentation February 06, 2018 Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements
More informationAlembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd Investor Presentation July-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Yearly Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual 7.
More informationAlembic Pharmaceuticals Ltd. Investor Presentation
Alembic Pharmaceuticals Ltd Investor Presentation October-2016 Contents 1. Milestones 2. Quarterly Highlights 3. Half yearly Highlights 4. Business - International - India Branded 5. Strategy 6. Financials
More informationAlembic Pharmaceuticals Ltd
Pharmaceuticals Ltd Investor Presentation January-2018 Contents 1. Milestones 2. Quarterly Highlights 3. Nine Months Highlights 4. Business - International - India 5. Strategy 6. Financials - Annual Safe
More informationStrong Margins, Robust Profitability Quarter I Results, FY EBITDA up 44%, Net profit up 43%
Strong Margins, Robust Profitability Quarter I Results, FY 2013 14 EBITDA up 44%, Net profit up 43% Mumbai, Aug 7, 2013: Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30
More informationInvestor Presentation
Investor Presentation www.ajantapharma.com 1 BSE Symbol : AJANTAPH Code: 532331 NSE Symbol : AJANTPHARM ISIN: INE031B01031 Safe Harbour Statement This presentation may include certain forward looking statements,
More informationViews on the Generics Market
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul, Turkey 15 th June 2007 Safe Harbor Except for
More informationALEMBIC PHARMACEUTICALS LTD.(APL)
ALEMBIC PHARMACEUTICALS LTD.(APL) Date : 13 th September, 212 Stock Performance Details Current Price : Rs. 73.35** Face Value : Rs. 2 per share 52 wk High / Low : Rs. 78.95 / Rs.34. Total Traded Volumes
More informationInvestor Presentation
Investor Presentation Q3 FY 15 Earnings Release 12 Feb 2015 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute
More informationLupin Ltd. Investor Presentation Q2 FY Oct 28, 2014
Lupin Ltd. Investor Presentation Q2 FY2014-15 Oct 28, 2014 Safe harbor statement Materials and information provided during this presentation may contain forward-looking statements. These statements are
More informationCase M TEVA/ALLERGAN GENERICS
EUROPEAN COMMISSION DG Competition Case M. 7746 TEVA/ALLERGAN GENERICS Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Decision on the implementation of remedies
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY14
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE FIRST QUARTER FY14 Revenue figures (Stand Alone) Particulars Un-audited Audited Quarter Ended Year Ended 30.06.13 31.03.13 30.06.12 % Gwth
More informationDr. Reddy s Q4 & FY15 Financial Results
PRESS RELEASE.. Dr. Reddy s Q4 & FY15 Financial Results Q4 FY15 Revenues at 38.7 billion FY15 Revenues at 148.2 billion (YoY growth of 11%) Q4 FY15 EBITDA at 8.1 billion (21% of revenues) (YoY growth of
More informationACETO Corporation NASDAQ: ACET. Investor Presentation February 2018
ACETO Corporation NASDAQ: ACET Investor Presentation February 218 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that
More informationVerson 2.0 Bigger, Better, Stronger
28 June 2016 CornerOffice Interaction with the CEO Verson 2.0 Bigger, Better, Stronger Size of a leader + growth of a start-up In the last four years, Aurobindo Pharma s PAT has grown 10x while its market
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global Healthcare Conference June 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect to our
More informationLUPIN LIMITED. Q2 FY17 Investor Presentation November 09, Aerial view of Lupin offices, Baltimore, US
LUPIN LIMITED Q2 FY17 Investor Presentation November 09, 2016 Safe Harbor Statement This report contains forward-looking statements that involve known and unknown risks, uncertainties and other factors
More informationACETO Corporation NASDAQ: ACET. Update May 2018
ACETO Corporation NASDAQ: ACET Update May 218 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can be identified
More informationACETO Corporation. June 8, 2016
NASDAQ:ACET ACETO Corporation Jefferies Healthcare Conference June 8, 2016 Sourcing & Supplying Quality Products Worldwide Disclosure This presentation contains forward-looking statements, as defined by
More informationQ3 FY09 Results Update
Q3 FY09 Results Update January 20, 2009 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking
More informationAceto Corporation. NASDAQ: ACET Investor Update November 2018
Aceto Corporation NASDAQ: ACET Investor Update November 2018 Disclosure This presentation contains forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, that can
More informationPrice regulation models in Turkey and the Russian Federation. Panos Kanavos London School of Economics NPPA Seminar, New Delhi, April 2008
Price regulation models in Turkey and the Russian Federation Panos Kanavos London School of Economics NPPA Seminar, New Delhi, April 2008 The context: Why Turkey and Russia? Attribute Implementing Health
More informationGeneric Medicine in South Africa Past, Present and Future. 15 th Annual IGPA Conference 2012 Kyoto - Japan. Dr. Fathima Docrat Chief Executive Officer
Generic Medicine in South Africa Past, Present and Future 15 th Annual IGPA Conference 2012 Kyoto - Japan The National Association of Pharmaceutical Manufacturers (NAPM), is a voluntary, nonprofit organization
More informationAurobindo Pharma ACCUMULATE. Performance Highlights. `780 Target Price CMP `855. 2QFY2019 Result Update Pharmaceutical. Investment Period 12 months
Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 Nov-17 Mar-18 Jul-18 Nov-18 2QFY2019 Result Update Pharmaceutical November 17, 2018 Aurobindo Pharma Performance Highlights Y/E march (` cr) 2QFY19 1QFY19 % chg
More informationJUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS
PRESS RELEASE Noida, Tuesday, May 24, 2016 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q4 & FY2016 RESULTS JUBILANT
More informationAurobindo Pharma Ltd.
. Volume No.. I Issue No. 165 Aurobindo Pharma Ltd. March 12, 2018 BSE Code: 524804 NSE Code: AUROPHARMA Reuters Code: ARBN.NS Bloomberg Code: ARBP:IN Aurobindo Pharma Ltd (Auro) is one of the largest
More informationPress Presentation Q4 18 & FY18
1 May 22, 2018 Q4 FY18 Press Meet Press Presentation Q4 18 & FY18 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationBird s Eye View of Indian Pharma
Bird s Eye View of Indian Pharma Classification of Pharma Industry Pharma industry Formulations Active Pharmaceuticals Ingredients Branded Generics Bulk drugs Pfizer Abbott GSK BMS Teva Mylan Dr Reddy
More informationInvestor Presentation Q2FY
Investor Presentation Q2FY19 05-11-2018 Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking
More informationPress Presentation- Q3 FY17. February 4th, 2017
Press Presentation- Q3 FY17 February 4th, 2017 Q3 Dr. FY17 Reddy s Press meet Laboratories Limited 1 Safe Harbor Statement This presentation contains forward-looking statements and information that involve
More informationDutch statutory board report and financial statements of Mylan N.V. for the fiscal year ended 31 December 2016
Dutch statutory board report and financial statements of Mylan N.V. for the fiscal year ended 31 December 2016 Mylan N.V. Dutch Statutory Board Report Table of Contents 1. Introduction................................................................................
More informationPress Presentation Q1 FY19
1 July 26, 2018 Q1 FY19 Press Meet Press Presentation Q1 FY19 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationAurobindo Pharma BUY. Performance Highlights CMP. `109 Target Price `156. 1QFY2013 Result Update Pharmaceutical. Investment Period 12 months
1QFY2013 Result Update Pharmaceutical August 8, 2012 Aurobindo Pharma Performance Highlights Y/E march (` cr) 1QFY2013 4QFY2012 % chg (qoq) 1QFY2012 % chg (yoy) Net sales 1197 1171 2.3 1065 12.4 Other
More informationPress Release. Consolidated Financial & Performance Highlights (Pharma & Biotech)
Press Release Strides Shasun announces Q1 FY17 results Q1 FY17 Pharma Revenues* at INR 8,699 Mn, Growth of 43% YoY, Pharma EBITDA at INR 1,451 Mn, Growth of 57% YoY Bengaluru, August 17, 2016: Strides
More informationAurobindo Pharma BUY. Performance Highlights CMP. `580 Target Price `823. 4QFY2017 Result Update Pharmaceutical. Investment Period 12 months
Nov-12 Jun-13 Dec-13 Jul-14 Jan-15 Aug-15 Feb-16 Sep-16 Apr-17 4QFY2017 Result Update Pharmaceutical June 2, 2017 Aurobindo Pharma Performance Highlights Y/E march (` cr) 4QFY17 3QFY17 % chg (QoQ) 4QFY16
More informationSWISS PARENTERALS LIMITED Regd Office: 304 Samaan 2, Opp Shell Pump, Nr Prahladnagar road, Satellite, Ahmedabad , ,
SWISS PARENTERALS LIMITED Regd Office: 304 Samaan 2, Opp Shell Pump, Nr Prahladnagar road, Satellite, Ahmedabad 380015, +91-79-71819191, nshah@swiss.in Nature of business Manufacturers and Exporters of
More informationAlembic Pharmaceuticals Ltd 25 th September, 2012
Company Report BROKING DEPOSITORY DISTRIBUTION FINANCIAL ADVISORY Alembic Pharmaceuticals Ltd 25 th September, 2012 CMP Target Price Rs.70.85 Rs.90.00 Alembic Pharma continues to maintain its market share
More informationAurobindo Pharma Ltd 27 th September 2010
CMP: Rs 1062.95 Recommendation: Buy Target Price: Rs 1250 Sector: Pharmaceuticals Market Data as on 24 th September 2010 Market Cap (Rs Mn) 60970 Free Float (Rs Mn) 27430 52 Week H/L 1110.0/681.10 Avg
More informationCadila Healthcare Ltd.
Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 s. Cadila Healthcare Ltd.. August 8, 216 BSE Code: 532321 NSE Code: CADILAHC Reuters Code: CADI.NS Bloomberg Code:
More informationNATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16
ISIN: INE987B01018 OCTOBER 15 th, 2015 STOCK DETAILS Sector NATCO PHARMA LTD. Result Update (PARENT BASIS): Q1 FY16 BSE Code 524816 Face Value 10.00 Pharmaceuticals 52wk. High / Low (Rs.) 2709.00/1245.40
More informationAurobindo Pharma BUY. Performance Highlights. `708 Target Price CMP `823. 2QFY2018 Result Update Pharmaceutical. Investment Period 12 months
Aug-14 Nov-14 Feb-15 May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 2QFY2018 Result Update Pharmaceutical November 20, 2017 Aurobindo Pharma Performance Highlights Y/E march
More informationJUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS
PRESS RELEASE Noida, Monday, Oct 22, 2018 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2 & H1 FY19 RESULTS JUBILANT
More informationAurobindo Pharma BUY. Performance Highlights CMP. `686 Target Price `877. 3QFY2017 Result Update Pharmaceutical. Investment Period 12 months
3QFY2017 Result Update Pharmaceutical February 23, 2017 Aurobindo Pharma Performance Highlights Y/E march (` cr) 3QFY17 2QFY17 % chg (QoQ) 3QFY16 % chg (yoy) Net sales 3,844 3,714 3.5 3,432 12.0 Other
More informationRanbaxy Q3 FY 2015 Sales Rs.25,876 Mn. YTD Dec 14 Sales Rs.81,778 Mn
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, Representative Director, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please
More informationAurobindo Pharma. Growth capsule. Detailed Report 18 February 2016 Sector: Healthcare
Detailed Report 18 February 2016 Sector: Healthcare Aurobindo Pharma Kumar Saurabh (Kumar.Saurabh@MotilalOswal.com); +91 22 3982 5584 Amey Chalke (Amey.Chalke@MotilalOswal.com); +91 22 39825423 Growth
More informationAkorn, Inc. N a s d a q : A K R X
Akorn, Inc. N a s d a q : A K R X Jefferies 2014 Global London Healthcare Conference November 2014 DISCLAIMER This presentation includes certain forward-looking statements regarding our views with respect
More informationDr Reddy s Laboratories Ltd. Q4 FY07 and FY07 Financial Performance Review
Dr Reddy s Laboratories Ltd. NYSE:RDY Q4 and Financial Performance Review Table of Contents USGAAP Financial Snapshot 02 Revenue Mix 03 Active Pharmaceutical Ingredients 04 Generic Formulations 05 Branded
More informationInitiating Coverage CMP: `610/- 10 th April 2018 BUY. Sector: Pharmaceuticals. Tausif Shaikh Tel:
Initiating Coverage CMP: `610/- 10 th April 2018 BUY Sector: Pharmaceuticals Tausif Shaikh Tel: +9122-6146 2974 tausifshaikh@way2wealth.com Company Details Key Stock Data CMP 610 Market Cap (` Crs) 35,734
More informationIndian Pharmaceutical Formulations Industry Report,
Indian Pharmaceutical Formulations Industry Report, 2008-2009 India plays an important role in the global pharmaceutical market. In 2005, 2/5 DMFs to FDA were submitted by India. Currently, there are more
More informationInvestor Presentation 2 nd Qtr. - FY 2018
Investor Presentation 2 nd Qtr. - FY 2018 31 st October, 2017 1 of 33 India Disclosure Index 2017 Ajanta s Ranking in Next 100 Listed Companies (Based on Market Cap) 1 st 2 nd 3 rd Voluntary Disclosure
More informationDr. Reddy s Q1 FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationDISHMAN CARBOGEN AMCIS LIMITED. Q3 & 9M FY18 RESULTS UPDATE January 2018
DISHMAN CARBOGEN AMCIS LIMITED Q3 & 9M FY18 RESULTS UPDATE January 2018 1 SAFE HARBOR STATEMENT This presentation and the following discussion may contain forward looking statements by Dishman Carbogen
More informationHIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007
HIKMA PHARMACEUTICALS PLC UBS GLOBAL GENERIC & SPECIALITY PHARMACEUTICALS CONFERENCE NEW YORK 8-9 MAY 2007 About Hikma Founded in Jordan in 1978 Multinational business developing, manufacturing and marketing
More informationJUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS
PRESS RELEASE Noida, Saturday, Oct 28, 2017 Jubilant Life Sciences Ltd. 1A, Sector 16A, Noida 201301, India Tel.: +91 120 4361000 http://www.jubl.com JUBILANT LIFE SCIENCES Q2/H1 FY2018 RESULTS The Board
More informationDr. Reddy s Q4 and FY16 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CONTACT
More informationAssessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU
White paper Assessing the impact of proposals for a Supplementary Protection Certificate (SPC) Manufacturing Exemption in the EU Ramya Logendra, Engagement Manager, Supplier and Association Relations Per
More informationPioneers of laminated tubes in India. Corporate Presentation
Pioneers of laminated tubes in India Corporate Presentation M17617 Safe Harbour Certain statements in this presentation concerning our future growth prospects are forward-looking statements. The Company
More informationDr. Reddy s Q1 FY18 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (PH: +91-40-4900 2135) CONTACT
More informationDr. Reddy s Q1 FY19 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CONTACT
More informationCambrex to Acquire Halo Pharma. July 23, 2018
Cambrex to Acquire Halo Pharma July 23, 2018 Forward-Looking Statements Statements in this presentation regarding the acquisition of Halo Pharma ( Halo ) and expected benefits therefrom (including revenue
More informationDr. Reddy s Laboratories Ltd Q3 FY12 Press Meet. February 03, 2012
Dr. Reddy s Laboratories Ltd Q3 FY12 Press Meet February 03, 2012 Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions.
More informationMACRO-ECONOMICS REGULATORY INFRASTRUCTURE PHARMA INDUSTRY
MACRO-ECONOMICS Economic growth are potentially good GDP per capita above $ 3.000 Government health budget increases to 5% Middle class category is projected into 150 Mn in 2014, average life expectancy
More informationINDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15. Revenue figures
INDOCO REMEDIES LIMITED MANAGEMENT DISCUSSION & ANALYSIS FOR THE SECOND QUARTER FY15 Revenue figures (` In Lacs) Unaudited Audited Particulars July 14 Sept. 14 Quarter Ended Apr. 14 Jun. 14 July 13 Sept.
More informationPhillips Carbon Black Limited January 2016
Phillips Carbon Black Limited www.pcblltd.com January 2016 1 The Group Companies RP- Sanjiv Goenka Group Power & Natural Resources Carbon Black Retail Media & Entertainment Infrastructur e IT & Education
More informationDec 01, 2016 LAURUS LABS LIMITED. SMC Ranking. (3/5) About the company. Issue Highlights. Strengths. Objects of the Issue. Shareholding Pattern (%)
LAURUS LABS LIMITED Dec 01, 2016 SMC Ranking (3/5) About the company Issue Highlights Industry Pharma Total Issue (Shares) - Offer for sale 24,844,240 Total Issue (Shares) - Fresh Issue 7,009,346 Net Offer
More informationAcquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma
NASDAQ: ACET ACETO Corporation Acquisition of Generic Drug-Related Assets of Citron Pharma and Lucid Pharma November 3, 2016 Disclosure This presentation contains forward-looking statements, as defined
More informationCatalent, Inc. Raymond James Institutional Investors Conference. March 7, 2016
Catalent, Inc. Raymond James Institutional Investors Conference March 7, 2016 Disclaimer Statement Forward-Looking Statements This press release contains both historical and forward-looking statements.
More informationJefferies Global Healthcare Conference
Jefferies Global Healthcare Conference June 7, 2012 2012 PAREXEL International Safe Harbor This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationAddressing access to healthcare
Addressing access to healthcare Karl Mahler Head Investor Relations René Imhof Head Operational Pricing Swiss Sustainability Leaders SRI Conference Buonas, 17 November 2014 This presentation contains certain
More informationPRESS MEET Q4 & FY14. Dr. Reddy s Laboratories Limited May 13, Dr. Reddy's Laboratories Limited. All Rights Reserved.
Dr. Reddy s Laboratories Limited May 13, 2014 Q4 FY 14 Business Highlights Sales Gross Profit 3,481 Cr 4.2 % 57.2 % 18 % YoYGr% to sales YoYGr% R & D Adj. EBITDA 11.4 % 71 % 22.8 % 2 %* to sales YoYGr%
More informationStrides Arcolab. On target. Strong product pipeline. Best in class marketing partners. Large manufacturing capacities. Improving financials
Initiating Coverage Sector: Pharmaceuticals Strides Arcolab Strong product pipeline Best in class marketing partners Large manufacturing capacities Improving financials Attractive valuations Amit Shah
More informationDr. Reddy s Q3 FY19 Financial Results
Press Release DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) CONTACT MEDIA
More informationDISCUSSION SUMMARY. Q1 FY15 Results Highlights About Us Q1 FY15 Consolidated Financials 14. Business Strategy & Outlook 17
DISHMAN PHARMACEUTICALS & CHEMICALS LIMITED Q1 FY15 QUARTERLY INVESTOR UPDATE AUGUST 2014 DISCUSSION SUMMARY Q1 FY15 Results Highlights 04 08 About Us 09 13 Q1 FY15 Consolidated Financials 14 Business
More informationAXA. Henri de Castries. Chairman & CEO. London - October 2, Sanford C. Bernstein Strategic Decisions Conference
AXA Henri de Castries Chairman & CEO London - October 2, 2013 Sanford C. Bernstein Strategic Decisions Conference Cautionary note concerning forward-looking statements Certain statements contained herein
More informationFor personal use only
MAYNE PHARMA ANNOUNCES ACQUISITION OF US GENERIC PRODUCT PORTFOLIO FROM TEVA AND ALLERGAN NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES 28 June 2016, Adelaide, South Australia Mayne Pharma Group
More informationAnnual General Meeting July 20, 2017
Annual General Meeting July 20, 2017 Forward Looking Statements Certain statements in this presentation are "forward-looking statements." These statements relate to future events or the Company's future
More information